IBX to access next generation MEMs imaging technology
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
13 July 2020
Imagion to work with Boston University on next generation imaging technology
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare
through the earlier detection of cancer, is pleased to announce it has become a member of the Nanosystems
Engineering Research Center at Boston University, where researchers are developing ultrasensitive
magnetic sensors that could greatly simplify the MagSense™ detection system. If successful, the new
sensors could enable the use of MagSense cancer detection technology in a doctor’s suite in addition to a
hospital imaging suite.
The Center, funded by the US National Science Foundation (NSF), is developing next generation cellular
metamaterials technologies with a primary focus on advancing nano-bio-manufacturing methods.
Membership provides Imagion with priority access to the new technologies and intellectual property being
developed at the Center. Of specific interest to Imagion is the Center’s advancements in the use of MicroElectro-Mechanical systems (MEMs) as ultrasensitive magnetometers which may have application in
detecting cardiovascular events and bio-medical imaging. MEMs are ubiquitous in everyday technologies
such as cellular phones and gaming devices providing functionality such as accelerometers, gyroscopes
and even in microphones. For Imagion, MEMs-based sensors could significantly reduce the size and cost
of the MagSense system by eliminating the requirement of using cryogenically cooled sensors, making it
both more affordable and portable like ultrasound equipment used in a doctor’s office.
“We are very excited by the research being done at Boston University on super small highly sensitive
magnetic sensors,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “Historically, we have
focused on using known technologies like superconducting quantum interference devices, so-called
SQUIDs, because they are proven technologies. Having visibility and access to cutting-edge innovative
technologies through our membership with the Center could enable us to produce imaging systems that
don’t need cryogenic cooling and are more versatile, expanding the commercial opportunity for our
MagSense system.”
“We are pleased to welcome Imagion Biosystems to the Center,” said Dr. David Bishop, Head of the Division
of Materials Science and Engineering at Boston University and Director of the Center. “We are always keen
to have industry partners as members to help focus our research projects on practical applications that can
translate from academic research to commercial value. We see Imagion’s MagSense technology as being
a good match and look forward to collaborating with them.”
About the Nanosystems Engineering Research Center
Officially known as the Nanosystems Engineering Research Center for Directed Multiscale Assembly of
Cellular Metamaterials with Nanoscale Precision (CELL-MET), the Center, led by Boston University, was
established to leverage the financial support provided by the National Science Foundation in creating
opportunities for public and private collaboration in research and development of new nanoscale
technologies. Industry and academic members of the Center provide input to research projects prioritized
by the Center and have priority access to inventions for research and commercial purposes.
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases
earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian
Securities Exchange (ASX) in June 2017.
-ENDS
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystem.com
®
For further information please visit www.imagionbiosystems.com
This Announcement has been approved by the Disclosure Committee of Imagion Biosystems
Limited.
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 401018828
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystem.com
Share your feedback
Discover